Sensei Biotherapeutics (SNSE) Competitors $0.32 +0.00 (+0.25%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNSE vs. QNTM, LVTX, COEP, SCLX, SCYX, DYAI, FGEN, MAAQ, MRNS, and GRCEShould you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Quantum Biopharma (QNTM), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), Scilex (SCLX), SCYNEXIS (SCYX), Dyadic International (DYAI), FibroGen (FGEN), Mana Capital Acquisition (MAAQ), Marinus Pharmaceuticals (MRNS), and Grace Therapeutics (GRCE). These companies are all part of the "pharmaceutical products" industry. Sensei Biotherapeutics vs. Quantum Biopharma LAVA Therapeutics Coeptis Therapeutics Scilex SCYNEXIS Dyadic International FibroGen Mana Capital Acquisition Marinus Pharmaceuticals Grace Therapeutics Quantum Biopharma (NASDAQ:QNTM) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings. Do insiders & institutionals have more ownership in QNTM or SNSE? 1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is QNTM or SNSE more profitable? Sensei Biotherapeutics' return on equity of -53.86% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Quantum BiopharmaN/A -84.21% -62.63% Sensei Biotherapeutics N/A -53.86%-46.91% Which has higher earnings and valuation, QNTM or SNSE? Quantum Biopharma is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuantum BiopharmaN/AN/A-$17.90M-$15.98-0.70Sensei BiotherapeuticsN/AN/A-$34.10M-$1.15-0.27 Which has more volatility & risk, QNTM or SNSE? Quantum Biopharma has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Does the media favor QNTM or SNSE? In the previous week, Quantum Biopharma had 4 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 4 mentions for Quantum Biopharma and 0 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.00 beat Quantum Biopharma's score of -0.75 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Quantum Biopharma Negative Sensei Biotherapeutics Neutral Does the MarketBeat Community favor QNTM or SNSE? Sensei Biotherapeutics received 31 more outperform votes than Quantum Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformQuantum BiopharmaN/AN/ASensei BiotherapeuticsOutperform Votes3181.58% Underperform Votes718.42% Do analysts rate QNTM or SNSE? Sensei Biotherapeutics has a consensus price target of $4.25, suggesting a potential upside of 1,279.87%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Quantum Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummarySensei Biotherapeutics beats Quantum Biopharma on 13 of the 15 factors compared between the two stocks. Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNSE vs. The Competition Export to ExcelMetricSensei BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.76M$6.47B$5.32B$8.43BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-0.269.0626.7719.71Price / SalesN/A254.27390.22118.35Price / CashN/A65.8538.2534.62Price / Book0.126.416.754.50Net Income-$34.10M$143.98M$3.23B$248.32M7 Day Performance-11.49%1.97%1.55%-0.09%1 Month Performance-11.03%4.09%12.22%12.89%1 Year Performance-77.35%-2.83%16.71%7.33% Sensei Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNSESensei Biotherapeutics3.9197 of 5 stars$0.32+0.2%$4.25+1,224.0%-77.1%$8.09MN/A-0.2740QNTMQuantum BiopharmaN/A$12.26+19.6%N/AN/A$33.18MN/A-0.80N/ANews CoverageLVTXLAVA Therapeutics2.216 of 5 stars$1.26+0.8%$3.17+151.3%-50.2%$33.14M$11.98M-1.2260Analyst RevisionGap DownCOEPCoeptis Therapeutics0.7074 of 5 stars$9.72-0.9%N/A+45.5%$32.71MN/A-1.682Positive NewsSCLXScilex1.5552 of 5 stars$4.70+11.6%$455.00+9,580.9%-87.8%$32.67M$56.59M-5.6680High Trading VolumeSCYXSCYNEXIS1.2992 of 5 stars$0.83+5.3%N/A-71.1%$32.43M$3.75M-1.1260Positive NewsEarnings ReportGap UpDYAIDyadic International2.2771 of 5 stars$1.06+1.9%$6.00+466.0%-38.3%$31.90M$3.50M-4.617FGENFibroGen4.377 of 5 stars$0.31+2.5%$10.00+3,088.8%-72.1%$31.69M$7.00M-0.25570MAAQMana Capital AcquisitionN/A$3.84-4.0%N/A+589.8%$31.20MN/A0.001High Trading VolumeMRNSMarinus Pharmaceuticals1.8807 of 5 stars$0.55-0.2%$4.79+771.6%-58.7%$30.32M$30.99M-0.22110News CoverageAnalyst ForecastGRCEGrace Therapeutics1.8472 of 5 stars$2.99+6.8%$12.00+301.3%N/A$30.32MN/A-2.58N/AGap Up Related Companies and Tools Related Companies QNTM Alternatives LVTX Alternatives COEP Alternatives SCLX Alternatives SCYX Alternatives DYAI Alternatives FGEN Alternatives MAAQ Alternatives MRNS Alternatives GRCE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNSE) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
